Panel discussion  - Pharma Strategy: Where do we start?

Information

  • Will the Pharma Strategy successfully tackle the onshoring of production of lifesaving pharmaceuticals? What is the timeline? 
  • How will an EU-wide reshoring strategy work alongside national programs? Could companies double up on incentives from member states and the EU? And is there a risk of member states competition over medicines manufacturing? 
  • Incentives, tax breaks, reduced barriers to entry... what are the most effective tools to strengthen European manufacturing and which combination will work best for both industry and patients? 
  • How quickly can it translate into concrete steps against shortages of medicines? 
  • Who is going to shoulder the added cost of EU-made medicines - pharma, health insurers, governments and taxpayers?   

Log in